An Italian panel of experts recommends using vitamin B6, dopamine agonists, and monoamine oxidase inhibitors (MAOIs) as first-line therapies for the treatment of people with rare aromatic l-amino acid decarboxylase (AADC) deficiency. Further, the expert panel called for an across-the-board, multidisciplinary approach for follow-up management of patients with the neurometabolic disease. On diagnostic procedures, the experts fully agree on the use of genetic analysis to diagnose adult-onset cases of AADC deficiency with mild symptoms. And,…

You must be logged in to read/download the full post.